Research and Markets (http://www.researchandmarkets.com/research/zlc7pp/metastatic) has announced the addition of the "Metastatic Ovarian Cancer-Pipeline Insights, 2016" report to their offering.
Metastatic Ovarian Cancer-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Metastatic Ovarian Cancer. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.
Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.
The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Metastatic Ovarian Cancer.
The report also assesses the Metastatic Ovarian Cancer therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.
Scope
- The report provides competitive pipeline landscape of Metastatic Ovarian Cancer
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Metastatic Ovarian Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Metastatic Ovarian Cancer and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Key Topics Covered:
- Metastatic Ovarian Cancer Overview
- Metastatic Ovarian Cancer Pipeline Therapeutics
- Metastatic Ovarian Cancer Therapeutics under Development by Companies
- Metastatic Ovarian Cancer Filed and Phase III Products
- Comparative Analysis
- Metastatic Ovarian Cancer Phase II Products
- Metastatic Ovarian Cancer Phase I and IND Filed Products
- Metastatic Ovarian Cancer Discovery and Pre-Clinical Stage Products
- Metastatic Ovarian Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Metastatic Ovarian Cancer - Discontinued Products
- Metastatic Ovarian Cancer - Dormant Products
- Companies Involved in Therapeutics Development for Metastatic Ovarian Cancer
For more information visit http://www.researchandmarkets.com/research/zlc7pp/metastatic
View source version on businesswire.com: http://www.businesswire.com/news/home/20160126006390/en/